title: [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
abstract: OBJECTIVE
  The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Twenty-seven PCOS overweight/obese patients were randomly treated: nine with only diet (D); nine with diet and metformin 1000 mg/day continuously (D+M); nine with diet, metformin 500 mg/day and MYO 4 g/day plus 400 µg folic acid daily, continuously (D+M+I). Menstrual cycle, Ferriman-Gallwey score, body mass index (BMI), waist hip rate (WHR), body composition by BIA 101 of AKERN SRL, were measured on basal condition and at 3 months.
  
  
  RESULTS
  Regularity of menstrual cycle was restored in a significantly number of patients of group D+M+I (P<0.05); Ferriman score was significantly improved by weight loss (P<0.05). Body weight, BMI, waist and hip circumferences decreased significantly in all groups without WHR modification; body weight loss significantly depended on adding metformin to diet. Fat mass (FM) kg and % was significantly reduced in groups D and D+M+I; fat free mass (FFM) kg was slightly reduced by diet (P<0.05) and correlated with Ferriman score.
  
  
  CONCLUSIONS
  Body weight loss in obese PCOS patients improves symptoms and body composition; weight loss was dependent on adding metformin to diet; MYO was more effective in restoring regularity of menstrual cycle. Further investigation occurs to confirm metformin and MYO rule on body composition improvement, specially regarding FFM that is likewise FM correlated to cardiovascular risk.
authors.affiliation: Dipartimento di Scienze Ginecologiche Ostetriche, Università di Messina, Messina, Italia. marialedonne@tin.it
authors.forename: M
authors.initials: M
authors.lastname: Le Donne
authors.forename: A
authors.initials: A
authors.lastname: Alibrandi
authors.forename: R
authors.initials: R
authors.lastname: Giarrusso
authors.forename: I
authors.initials: I
authors.lastname: Lo Monaco
authors.forename: U
authors.initials: U
authors.lastname: Muraca
mesh_terms: D000293:Adolescent; D000328:Adult; D001823:Body Composition / Q000187:drug effects*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007294:Inositol / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000178:diet therapy* / Q000188:drug therapy*; D050177:Overweight / Q000150:complications / Q000178:diet therapy* / Q000188:drug therapy*; D011085:Polycystic Ovary Syndrome / Q000150:complications*; D014803:Vitamin B Complex / Q000494:pharmacology / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D014803:Vitamin B Complex; D007294:Inositol; D008687:Metformin